Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Pyxis Oncology, Inc. (PYXS : NSDQ)

• Company Description    Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass. Number of Employees: 56

• Price / Volume Information    Yesterday's Closing Price: $2.61 Daily Weekly Monthly 20 Day Moving Average: 1,600,102 shares Shares Outstanding: 63.35 (millions) Market Capitalization: $165.36 (millions) Beta: 1.30 52 Week High: $5.55 52 Week Low: $0.97 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 17.04% 16.18% 12 Week 53.53% 49.32% Year To Date 126.96% 115.34%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 321 HARRISON AVENUE - BOSTON,MA 02118 USA ph: 617-453-3596 fax: - ir@pyxisoncology.com http://www.pyxisoncology.com

• General Corporate Information    Officers Thomas Civik - Interim Chief Executive Officer; Director John Flavin - Chairman of the Board of Directors Jitendra Wadhane - Principal Financial and Accounting Officer Darren Cline - Director Freda Lewis-Hall - Director Peer Information Pyxis Oncology, Inc. (GSAC) Pyxis Oncology, Inc. (CASIF) Pyxis Oncology, Inc. (ALCD.) Pyxis Oncology, Inc. (OMNN) Pyxis Oncology, Inc. (CGPI.) Pyxis Oncology, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 747324101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 63.35 Most Recent Split Date: (:1) Beta: 1.30 Market Capitalization: $165.36 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.27 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.19 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.25 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -5.71% vs. Previous Quarter: -27.59% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -135.60 12/31/25 - -101.77 ROA 06/30/26 - - 03/31/26 - -85.00 12/31/25 - -69.81 Current Ratio 06/30/26 - - 03/31/26 - 2.76 12/31/25 - 3.41 Quick Ratio 06/30/26 - - 03/31/26 - 2.76 12/31/25 - 3.41 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - -579.80 12/31/25 - -564.55 Book Value 06/30/26 - - 03/31/26 - 0.50 12/31/25 - 0.86 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©